Tyr767

Tyr767

Javascript is not enabled on this browser. This site will not work properly without Javascript.

PhosphoSitePlus Homepage

PhosphoSitePlus^® v6.7.9

Powered by Cell Signaling Technology

Home > Phosphorylation Site Page: > Tyr767 - gp130 (human)

Site Information
StVVHsGyRHQVPSV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 450053

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 7 , 8 )
Disease tissue studied:	gastric cancer ( 5 , 6 ) , gastric carcinoma ( 5 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 5 ) , non-small cell squamous cell lung carcinoma ( 1 , 5 ) , ovarian cancer ( 4 ) , ovarian epithelial carcinoma ( 4 ) , thymic carcinoma ( 2 , 3 )
Relevant cell line - cell type - tissue:	'brain, embryonic' ( 8 ) , BaF3 ('B lymphocyte, precursor') ( 7 ) , hepatocyte-liver ( 8 ) , HepG2 (hepatic) ( 7 ) , lymphocyte-spleen ( 8 ) , MKN-45 (gastric) ( 5 , 6 ) , NCI-H1703 (squamous) ( 1 , 5 ) , NCI-H3255 (pulmonary) ( 5 ) , OVMANA (ovarian) ( 4 ) , thymus ( 2 , 3 )

Upstream Regulation
Treatments:	Su11274 ( 5 )

Downstream Regulation
Effects of modification on biological processes:	cell cycle regulation ( 7 ) , transcription, altered ( 7 )

References
1	Rikova K (2012) CST Curation Set: 16139; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954 Curated Info
2	Li Y (2011) CST Curation Set: 10459; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
3	Li Y (2011) CST Curation Set: 10460; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
4	Ren H (2011) CST Curation Set: 11303; Year: 2011; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
5	Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64 20736484 Curated Info
6	Moritz A (2008) CST Curation Set: 5772; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
7	Schmitz J, et al. (2000) The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction. J Immunol 164, 848-54 10623831 Curated Info
8	Ohtani T, et al. (2000) Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12, 95-105 10661409 Curated Info

Developed with grants from

and literature mining with Linguamatics

Creative Commons License

PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.